Bristol Myers Squibb (BMY) announced that the European Medicines Agency (EMA) has validated its type II variation application for immunotherapy drug Opdivo (nivolumab), in combination with Yervoy (ipilimumab).The application seeks approval of Opdivo plus Yervoy as a potential first-line treatment option for adult patients with unresectable or advanced hepatocellular carcinoma (HCC) who have not received any prior systemic therapy.The application is based on results from the late-stage CheckMate -9DW trial, ...